SmithKline consumer health sales jump 21% not including Sterling contribution.
This article was originally published in The Tan Sheet
SMITHKLINE CONSUMER HEALTHCARE SALES JUMP 21% IN THIRD QUARTER, not including the contribution from Sterling Winthrop's non-U.S. business acquired last year. Including the contribution from the Sterling acquisition, SmithKline Beecham's overall consumer healthcare sales rose 51% in the quarter to [pound]538 mil., or $855 mil. (based on the currency translation of [pound]=$1.59 and assuming comparable exchange rates). The consumer segment's operating profit increased 73% to [pound]104, or $165 mil., in the quarter
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.